Ensartinib (X-396), a second-generation ALK TKI, in Chinese ALK-positive non-small cell lung cancer: A phase I, dose-escalation study

    Journal of Clinical Oncology, 2018.

    Cited by: 0|Bibtex|Views4|

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments